Legal & General Group Plc Buys Shares of 109,870 Prestige Consumer Healthcare Inc. $PBH

Legal & General Group Plc purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the second quarter, HoldingsChannel.com reports. The fund purchased 109,870 shares of the company’s stock, valued at approximately $5,194,000.

Several other institutional investors have also modified their holdings of the business. BlackRock Inc. acquired a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at approximately $370,187,000. Dimensional Fund Advisors LP lifted its stake in Prestige Consumer Healthcare by 3.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company’s stock valued at $158,414,000 after buying an additional 91,710 shares in the last quarter. State Street Corp lifted its stake in Prestige Consumer Healthcare by 1.4% in the fourth quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after buying an additional 27,721 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Prestige Consumer Healthcare by 6.3% in the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after buying an additional 71,078 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Prestige Consumer Healthcare by 5.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock worth $45,568,000 after acquiring an additional 35,126 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Finally, Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $52.63 on Friday. The company has a quick ratio of 1.99, a current ratio of 3.23 and a debt-to-equity ratio of 1.06. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $71.07. The stock has a market capitalization of $2.49 billion, a P/E ratio of 14.74, a P/E/G ratio of 1.66 and a beta of 0.33. The company has a 50 day moving average of $50.70 and a 200-day moving average of $54.15.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. During the same quarter in the previous year, the firm posted $0.90 earnings per share. The firm’s revenue for the quarter was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).